Literature DB >> 6173323

Gamma interferon production by combinations of human peripheral blood lymphocytes, monocytes, and cultured macrophages.

R D Arbeit, P L Leary, M J Levin.   

Abstract

Mitogen-induced interferon (IFN) production was studied using human peripheral blood mononuclear cells and subpopulations of lymphocytes, monocytes, and cultured macrophages. Cell populations were prepared in suspension to permit quantitative analysis of the interactions among different cell types. After stimulation by staphylococcal enterotoxin A, nylon column-purified lymphocytes produced only 5% as much IFN as the peripheral blood mononuclear cells from which they were prepared. When lymphocytes were supplemented with as little as 2% monocytes, IFN production increased two- to eightfold; with the addition of up to 20% monocytes, IFN production increased further, to levels approximating those of peripheral blood mononuclear cells. Monocytes alone produced no or very little IFN. Macrophages were derived from monocytes by culturing in vitro for 7 days. The addition of 2 to 5% autologous macrophages augmented IFN production to the same extent as 2 to 5% monocytes. However, more macrophages consistently resulted in less, rather than more, IFN, so that lymphocytes with 20% monocytes produced three- to eightfold more IFN than did lymphocytes with 20% macrophages. Thus, whereas the addition of monocytes over a broad dose-response range (2 to 20%) progressively augmented IFN production, macrophages showed an optimal effect at 2 to 5%, with higher percentages being inhibitory. The IFN induced by stimulation with staphylococcal enterotoxin A was characterized as IFN-gamma by its resistance to neutralization by antibody to IFN- alpha and its inability to induce antiviral protection in embryonic bovine trachea cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173323      PMCID: PMC351050          DOI: 10.1128/iai.35.2.383-390.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Human monocyte and macrophage modulation of lymphocyte proliferation.

Authors:  J J Rinehart; M Orser; M E Kaplan
Journal:  Cell Immunol       Date:  1979-04       Impact factor: 4.868

2.  Proliferative and interferon responses by peripheral blood mononuclear cells after bone marrow transplantation in humans.

Authors:  M J Levin; R Parkman; M N Oxman; J M Rappeport; M Simpson; P L Leary
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

3.  Immune interferon. I. Production by lymphokine-activated murine macrophages.

Authors:  C Neumann; C Sorg
Journal:  Eur J Immunol       Date:  1977-10       Impact factor: 5.532

4.  Pronounced antiviral activity of human interferon on bovine and porcine cells.

Authors:  I Gresser; M T Bandu; D Brouty-boye; M Tovey
Journal:  Nature       Date:  1974-10-11       Impact factor: 49.962

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Production of high-titered interferon in cultures of human diploid cells.

Authors:  E A Havell; J Vilcek
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

Review 7.  Suppressor cells in the regulation of the immune response.

Authors:  T A Waldmann; S Broder
Journal:  Prog Clin Immunol       Date:  1977

8.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

9.  Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes.

Authors:  M P Langford; G J Stanton; H M Johnson
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

10.  Antibody to staphylococcal enterotoxin A-induced human immune interferon (IFN gamma).

Authors:  M P Langford; D A Weigent; J A Georgiades; H M Johnson; G J Stanton
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

View more
  9 in total

1.  Natural killing of fibroblasts infected with low-passage clinical isolates of human cytomegalovirus.

Authors:  S Bandyopadhyay; S H Oh; S Michelson; D S Miller; J L Virelizier; S E Starr
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

2.  Deficient immune interferon production in tuberculosis.

Authors:  J K Onwubalili; G M Scott; J A Robinson
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

3.  Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies.

Authors:  C B Wilson; J Westall; L Johnston; D B Lewis; S K Dower; A R Alpert
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro.

Authors:  S P Sylvan; U B Hellström
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

Review 5.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Purification of a factor which provides a costimulatory signal for gamma interferon production.

Authors:  K Nakamura; H Okamura; K Nagata; T Komatsu; T Tamura
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

7.  Stably expressed antisense RNA to cytomegalovirus UL83 inhibits viral replication.

Authors:  P Dal Monte; C Bessia; A Ripalti; M P Landini; A Topilko; B Plachter; J L Virelizier; S Michelson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Characterization of human interferon-gamma-producing leukocytes with monoclonal antileukocyte antibodies.

Authors:  J Abb; H Abb; F Deinhardt
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

9.  Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1.

Authors:  S Bandyopadhyay; U Ziegner; D E Campbell; D S Miller; J A Hoxie; S E Starr
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.